Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cadrenal Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CVKD
Nasdaq
2834
www.cadrenal.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
- Oct 7th, 2026 5:00 am
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
- Sep 21st, 2026 2:30 pm
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
- Sep 3rd, 2026 6:00 am
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
- Aug 31st, 2026 6:00 am
CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
- Aug 31st, 2026 5:03 am
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
- Aug 13th, 2026 2:15 pm
CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy
- Aug 3rd, 2026 10:15 am
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
- Aug 3rd, 2026 6:30 am
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
- Jul 21st, 2026 6:00 am
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
- Jul 13th, 2026 7:00 am
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Jun 30th, 2026 6:00 pm
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
- Jun 24th, 2026 6:00 am
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
- Jun 18th, 2026 7:00 am
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
- Jun 15th, 2026 6:30 am
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
- Jun 3rd, 2026 7:00 am
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
- May 19th, 2026 2:30 pm
CVKD: Designing Phase 3 Trial for CAD-1005 in HIT
- May 8th, 2026 6:15 am
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
- Apr 30th, 2026 6:30 am
Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program
- Apr 20th, 2026 8:47 pm
Scroll